Novartis announced today that the US Food and Drug Administration (FDA) has approved a label update for Leqvio® (inclisiran), enabling its use as monotherapy along with diet and exercise to reduce low ...

The updated label no longer requires Leqvio (inclisiran) to be used in combination with statins for low-density lipoprotein ...

The update was requested by the FDA based on data supporting the significant LDL-C lowering abilities of PCSK-targeting therapies.

Novartis announced the FDA approved updated labeling for inclisiran, a small-interfering RNA therapy, for use as monotherapy ...

2022年6月18日，中国科学院上海药物研究所南发俊课题组和李静雅课题组合作在Acta Pharmaceutica Sinica B上发表文章“Development of the novel ACLY inhibitor 326E as a promising treatment for hypercholesterolemia”，在高胆固醇血症靶向治疗策略中取得重要进展 ...

SaveHealth reports that high cholesterol affects 1 in 3 Americans, often without symptoms until serious events occur. It is ...

具体来说，他们要么患有杂合子家族性高胆固醇血症（Heterozygous Familial Hypercholesterolemia, HeFH），这是一种遗传性疾病，导致 LDL 胆固醇水平天生就很 ...

A fter finding out you have hypercholesterolemia, your medical team may recommend medication to lower your high cholesterol levels and thus reduce your risk of heart attack, stroke, and other ...

Diagnosis Hypercholesterolemia does not usually present with any symptoms and the only way to check for the condition is to perform a check of the blood cholesterol level, referred to as a lipid ...

Correspondence Hypercholesterolemia in Primary Biliary Cirrhosis Published October 11, 2007 N Engl J Med 2007;357: 1561 - 1562 DOI: 10.1056/NEJMc071467 ...